Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > REGULATORY
REGULATORY
- MHLW’s Generic Roadmap Compilation in Homestretch
March 29, 2013
- MHLW Committee Calls for New Name for Norvasc or Nolvadex to Prevent Further Prescribing Errors
March 29, 2013
- PFSB Notification Calls for Revisions of Precautions for Gabapentin, Other Drugs
March 28, 2013
- MHLW to Request Development of 2 Unapproved Indications Determined to Have Unmet Medical Needs
March 27, 2013
- PAFSC Committee Approves Reclassification of Tiquizium Bromide and Diclofenac as Class 2 OTC Drugs
March 26, 2013
- Administrative Evaluation: Health Ministry Urged to Review All-Specification Listing Requirement for Generics
March 25, 2013
- LDP Subcommittee Begins Discussions on Amending PAL; Bill Expected to Be Submitted During Current Diet Session
March 25, 2013
- Regulatory Reform Council Not Convinced of MHLW’s Response to Online Sale of OTC Drugs
March 25, 2013
- CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
- PMDA’s FY2013 Project Plan OK’d; Discussions for 3rd Mid-Term Plan to Get Underway
March 21, 2013
- Government’s New Office to Compile Health and Medical Strategy by June, Appoints JPMA Teshirogi as Advisor
March 21, 2013
- PMDA Testing New System that Uses Electronic Medical Information to Help Assess Post-Marketing Drug Risk
March 21, 2013
- MHLW Announces 4-Year Extension of Reexamination Period for Adoair
March 21, 2013
- MHLW Issues Notification on Revised GVP, GPSP Ordinances
March 19, 2013
- LDP to Begin Discussions on Bill to Amend PAL; MHLW Aims to Submit Bill during Current Diet Session
March 19, 2013
- Payer Representative Tsuyoshi Kobayashi Questions Automatic Health Insurance Coverage for Additional Indications
March 15, 2013
- Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
- PAFSC’s Second Committee Recommends Approval for Pfizer’s JAK Inhibitor Xeljanz, Others
March 14, 2013
- LDP Policy Subcommittee Demands Ban on Mixed Healthcare in TPP Talks
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…